Xiaohong Ma

488 total citations
22 papers, 305 citations indexed

About

Xiaohong Ma is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiaohong Ma has authored 22 papers receiving a total of 305 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaohong Ma's work include Cancer, Lipids, and Metabolism (5 papers), Ferroptosis and cancer prognosis (3 papers) and Cancer-related molecular mechanisms research (3 papers). Xiaohong Ma is often cited by papers focused on Cancer, Lipids, and Metabolism (5 papers), Ferroptosis and cancer prognosis (3 papers) and Cancer-related molecular mechanisms research (3 papers). Xiaohong Ma collaborates with scholars based in China and United States. Xiaohong Ma's co-authors include Jie Jiang, Zhiming Liu, Chunping Qiu, Lina Wei, Tianyi Zhao, Wenzhi Li, Yixin Hou, Shanshan Xiong, Qing Zhou and Gaoliang Ouyang and has published in prestigious journals such as Scientific Reports, Biochemical and Biophysical Research Communications and British Journal of Cancer.

In The Last Decade

Xiaohong Ma

17 papers receiving 301 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaohong Ma China 10 161 105 84 50 45 22 305
Mitsuyo Yoshida Japan 12 167 1.0× 108 1.0× 121 1.4× 92 1.8× 18 0.4× 20 354
Perrine Garde‐Granger Canada 11 125 0.8× 52 0.5× 166 2.0× 117 2.3× 36 0.8× 12 349
Jodi A. McKenzie United States 8 155 1.0× 54 0.5× 121 1.4× 81 1.6× 73 1.6× 30 302
Haruko Kunitomi Japan 9 183 1.1× 112 1.1× 71 0.8× 16 0.3× 34 0.8× 17 311
Jitka Hausnerová Czechia 10 142 0.9× 93 0.9× 70 0.8× 23 0.5× 34 0.8× 37 297
K Ashihara Japan 11 200 1.2× 141 1.3× 139 1.7× 53 1.1× 29 0.6× 16 407
Ziyang Di China 8 326 2.0× 223 2.1× 114 1.4× 46 0.9× 92 2.0× 11 448
Guoli Shao China 11 249 1.5× 190 1.8× 73 0.9× 44 0.9× 42 0.9× 18 382
Xiangyan Jiang China 12 203 1.3× 83 0.8× 159 1.9× 74 1.5× 85 1.9× 26 409

Countries citing papers authored by Xiaohong Ma

Since Specialization
Citations

This map shows the geographic impact of Xiaohong Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaohong Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaohong Ma more than expected).

Fields of papers citing papers by Xiaohong Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaohong Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaohong Ma. The network helps show where Xiaohong Ma may publish in the future.

Co-authorship network of co-authors of Xiaohong Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaohong Ma. A scholar is included among the top collaborators of Xiaohong Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaohong Ma. Xiaohong Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sun, Rui, Ying Zhao, Yao Liu, et al.. (2025). Extracellular matrix stiffness in endometrial cancer: driving progression and modulating treatment sensitivity via the ROCK1/YAP1 axis. Cell Death and Disease. 16(1). 380–380. 2 indexed citations
2.
Yang, Yingying, Di Sun, Xiaohong Ma, Tianqi Wang, & Jitao Wu. (2025). CD68- and CD163-positive tumor-associated macrophages in renal clear cell carcinoma. Scientific Reports. 15(1). 35138–35138.
3.
4.
5.
Cui, Ming, Xiaohong Ma, Yan Wang, et al.. (2025). Overexpression of the ferroptosis-related gene, NFS1, corresponds to gastric cancer growth and tumor immune infiltration. Open Life Sciences. 20(1). 20251135–20251135.
6.
7.
8.
Zhou, Qing, Wenzhi Li, Yao Liu, et al.. (2023). LncRNA HOXB-AS3 binding to PTBP1 protein regulates lipid metabolism by targeting SREBP1 in endometrioid carcinoma. Life Sciences. 320. 121512–121512. 7 indexed citations
9.
Wei, Lina, Xiaohong Ma, Yixin Hou, et al.. (2023). Verteporfin reverses progestin resistance through YAP/TAZ-PI3K-Akt pathway in endometrial carcinoma. Cell Death Discovery. 9(1). 30–30. 18 indexed citations
10.
Wang, Tianqi, et al.. (2023). Expression of EPB41L2 in Cancer-Associated Fibroblasts: Prognostic Implications for Bladder Cancer and Response to Immunotherapy. Archives of Medical Research. 55(1). 102927–102927. 4 indexed citations
11.
Ma, Xiaohong, Min Xia, Lina Wei, et al.. (2022). ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by targeting MGLL. Cell Death and Disease. 13(12). 1067–1067. 8 indexed citations
12.
Zhao, Tianyi, Rui Sun, Xiaohong Ma, et al.. (2022). Overexpression of LPCAT1 enhances endometrial cancer stemness and metastasis by changing lipid components and activating TGF-β/Smad2/3 signaling pathway. Acta Biochimica et Biophysica Sinica. 54(7). 904–916. 20 indexed citations
13.
14.
Ma, Xiaohong, Tianyi Zhao, Hong Yan, et al.. (2021). Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma. Cell Death and Disease. 12(6). 544–544. 42 indexed citations
15.
16.
Ding, Fei, Chunping Qiu, Wenzhi Li, et al.. (2021). CNR1 may reverse progesterone-resistance of endometrial cancer through the ERK pathway. Biochemical and Biophysical Research Communications. 548. 148–154. 9 indexed citations
17.
Zhao, Tianyi, Yifang Zhang, Xiaohong Ma, et al.. (2021). Elevated expression of LPCAT1 predicts a poor prognosis and is correlated with the tumour microenvironment in endometrial cancer. Cancer Cell International. 21(1). 269–269. 16 indexed citations
18.
Sun, Aixia, Cody Pinger, Xiaohong Ma, et al.. (2020). Artificial Intelligence Analysis of Magnetic Particle Imaging for Islet Transplantation in a Mouse Model. Molecular Imaging and Biology. 23(1). 18–29. 25 indexed citations
19.
Zhou, Qing, Wenzhi Li, Zhiming Liu, et al.. (2019). DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma. Cancer Medicine. 8(9). 4380–4388. 16 indexed citations
20.
Li, Wenzhi, Shufen Wang, Chunping Qiu, et al.. (2019). Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line. Journal of Translational Medicine. 17(1). 58–58. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mitsuyo Yoshida Breakdown of academic impact, for papers by Perrine Garde‐Granger Breakdown of academic impact, for papers by Jodi A. McKenzie Breakdown of academic impact, for papers by Haruko Kunitomi Breakdown of academic impact, for papers by Jitka Hausnerová Breakdown of academic impact, for papers by K Ashihara Breakdown of academic impact, for papers by Ziyang Di Breakdown of academic impact, for papers by Guoli Shao Breakdown of academic impact, for papers by Xiangyan Jiang
Rankless by CCL
2026